Fundació ACE

Sept. 2016 - ongoing

Barcelona (Spain)

A prospective cohort of consecutive patients attended in the Memory clinic of ACE Alzheimer Center Barcelona (Spain) with follow up of participants forward in time from exposure to outcome (ie disease progression). 

1. Agency for Innovation and Entrepreneurship (VLAIO). grant Nº PR067/21 for the HARPONE project
2. ADAPTED project the EU/EFPIA Innovative Medicines Initiative Joint Undertaking Grant Nº 115975.
3. The Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud integrated in the Spanish National R+D+I Plan and funded by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa") grants PI17/01474, PI19/00335, PI22/01403 and PI22/00258.
4. CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010.
5. PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097
6. DESCARTES project, German Research Foundation (DFG).
7. Fundación bancaria “La Caixa”
8. Fundación ADEY,
9. Fundación Echevarne
10. Grífols SA (GR@ACE and FACEHBI projects).

Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. 

Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. 

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment. 

Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic. 

Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia. 

Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer's disease. 

https://www.fundacioace.com/en